DE69738462T2 - Bioresorbierbare medizinische Vorrichtungen aus oxidierten Polysacchariden - Google Patents
Bioresorbierbare medizinische Vorrichtungen aus oxidierten Polysacchariden Download PDFInfo
- Publication number
- DE69738462T2 DE69738462T2 DE69738462T DE69738462T DE69738462T2 DE 69738462 T2 DE69738462 T2 DE 69738462T2 DE 69738462 T DE69738462 T DE 69738462T DE 69738462 T DE69738462 T DE 69738462T DE 69738462 T2 DE69738462 T2 DE 69738462T2
- Authority
- DE
- Germany
- Prior art keywords
- oxidized
- cellulose
- bioabsorbable
- water
- cellulose derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 150000004676 glycans Chemical class 0.000 title claims description 3
- 229920001282 polysaccharide Polymers 0.000 title claims description 3
- 239000005017 polysaccharide Substances 0.000 title claims description 3
- 229920000609 methyl cellulose Polymers 0.000 claims description 66
- 239000001923 methylcellulose Substances 0.000 claims description 66
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 59
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 53
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 52
- 229920002678 cellulose Polymers 0.000 claims description 52
- 239000001913 cellulose Substances 0.000 claims description 52
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 50
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 50
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 45
- 239000000463 material Substances 0.000 claims description 42
- MGWGWNFMUOTEHG-UHFFFAOYSA-N 4-(3,5-dimethylphenyl)-1,3-thiazol-2-amine Chemical compound CC1=CC(C)=CC(C=2N=C(N)SC=2)=C1 MGWGWNFMUOTEHG-UHFFFAOYSA-N 0.000 claims description 39
- JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 claims description 39
- 238000000034 method Methods 0.000 claims description 37
- 239000000499 gel Substances 0.000 claims description 22
- 230000003647 oxidation Effects 0.000 claims description 22
- 238000007254 oxidation reaction Methods 0.000 claims description 22
- 239000004744 fabric Substances 0.000 claims description 19
- 238000006467 substitution reaction Methods 0.000 claims description 18
- 229920002201 Oxidized cellulose Polymers 0.000 claims description 16
- 229940107304 oxidized cellulose Drugs 0.000 claims description 15
- WFPZPJSADLPSON-UHFFFAOYSA-N dinitrogen tetraoxide Chemical compound [O-][N+](=O)[N+]([O-])=O WFPZPJSADLPSON-UHFFFAOYSA-N 0.000 claims description 14
- 229920002301 cellulose acetate Polymers 0.000 claims description 13
- 230000008569 process Effects 0.000 claims description 13
- 239000004753 textile Substances 0.000 claims description 11
- 239000002904 solvent Substances 0.000 claims description 10
- 239000007800 oxidant agent Substances 0.000 claims description 8
- 238000005406 washing Methods 0.000 claims description 8
- 230000001590 oxidative effect Effects 0.000 claims description 7
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- 229920002674 hyaluronan Polymers 0.000 claims description 6
- 229960003160 hyaluronic acid Drugs 0.000 claims description 6
- 125000000075 primary alcohol group Chemical group 0.000 claims description 3
- 239000000758 substrate Substances 0.000 claims description 3
- 102000008186 Collagen Human genes 0.000 claims description 2
- 108010035532 Collagen Proteins 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 2
- 229920002732 Polyanhydride Polymers 0.000 claims description 2
- 229920000954 Polyglycolide Polymers 0.000 claims description 2
- -1 Polyphospan Polymers 0.000 claims description 2
- 229920001436 collagen Polymers 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 3
- 239000002243 precursor Substances 0.000 claims 3
- 150000001735 carboxylic acids Chemical class 0.000 claims 2
- 102000016942 Elastin Human genes 0.000 claims 1
- 108010014258 Elastin Proteins 0.000 claims 1
- 229920001710 Polyorthoester Polymers 0.000 claims 1
- 229920002549 elastin Polymers 0.000 claims 1
- 229920000747 poly(lactic acid) Polymers 0.000 claims 1
- 239000002745 poly(ortho ester) Substances 0.000 claims 1
- 229920002463 poly(p-dioxanone) polymer Polymers 0.000 claims 1
- 229920001610 polycaprolactone Polymers 0.000 claims 1
- 239000004632 polycaprolactone Substances 0.000 claims 1
- 239000000622 polydioxanone Substances 0.000 claims 1
- 150000005846 sugar alcohols Polymers 0.000 claims 1
- 235000010981 methylcellulose Nutrition 0.000 description 63
- 239000000243 solution Substances 0.000 description 62
- 239000010408 film Substances 0.000 description 52
- 235000010980 cellulose Nutrition 0.000 description 40
- 229920000642 polymer Polymers 0.000 description 37
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 30
- 239000004033 plastic Substances 0.000 description 26
- 229920003023 plastic Polymers 0.000 description 26
- 239000007789 gas Substances 0.000 description 23
- 239000000843 powder Substances 0.000 description 22
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 19
- 239000007864 aqueous solution Substances 0.000 description 15
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 14
- 238000001356 surgical procedure Methods 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 12
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 10
- 241000283973 Oryctolagus cuniculus Species 0.000 description 9
- 230000004888 barrier function Effects 0.000 description 9
- 239000002131 composite material Substances 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 8
- 239000011521 glass Substances 0.000 description 8
- 229920003091 Methocel™ Polymers 0.000 description 7
- 229920000297 Rayon Polymers 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 229910001873 dinitrogen Inorganic materials 0.000 description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
- 206010052428 Wound Diseases 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 6
- 230000000740 bleeding effect Effects 0.000 description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 230000005855 radiation Effects 0.000 description 6
- 239000002964 rayon Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 208000031737 Tissue Adhesions Diseases 0.000 description 5
- 210000001015 abdomen Anatomy 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 210000000038 chest Anatomy 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- FZWBNHMXJMCXLU-UHFFFAOYSA-N 2,3,4,5-tetrahydroxy-6-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxyhexanal Chemical compound OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OCC(O)C(O)C(O)C(O)C=O)O1 FZWBNHMXJMCXLU-UHFFFAOYSA-N 0.000 description 4
- 206010003210 Arteriosclerosis Diseases 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 229940119743 dextran 70 Drugs 0.000 description 4
- 230000002526 effect on cardiovascular system Effects 0.000 description 4
- 239000012442 inert solvent Substances 0.000 description 4
- 238000010253 intravenous injection Methods 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 229920002307 Dextran Polymers 0.000 description 3
- 239000001856 Ethyl cellulose Substances 0.000 description 3
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 3
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 239000003518 caustics Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 229910003460 diamond Inorganic materials 0.000 description 3
- 239000010432 diamond Substances 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 235000019325 ethyl cellulose Nutrition 0.000 description 3
- 229920001249 ethyl cellulose Polymers 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 238000002682 general surgery Methods 0.000 description 3
- 239000002874 hemostatic agent Substances 0.000 description 3
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 229920002521 macromolecule Polymers 0.000 description 3
- 210000003516 pericardium Anatomy 0.000 description 3
- 239000004627 regenerated cellulose Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 210000001562 sternum Anatomy 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 2
- AJDIZQLSFPQPEY-UHFFFAOYSA-N 1,1,2-Trichlorotrifluoroethane Chemical compound FC(F)(Cl)C(F)(Cl)Cl AJDIZQLSFPQPEY-UHFFFAOYSA-N 0.000 description 2
- 206010000050 Abdominal adhesions Diseases 0.000 description 2
- 229920013683 Celanese Polymers 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 206010060932 Postoperative adhesion Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002385 Sodium hyaluronate Polymers 0.000 description 2
- 238000002679 ablation Methods 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 229940030225 antihemorrhagics Drugs 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 229920003086 cellulose ether Polymers 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- SWXVUIWOUIDPGS-UHFFFAOYSA-N diacetone alcohol Natural products CC(=O)CC(C)(C)O SWXVUIWOUIDPGS-UHFFFAOYSA-N 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 235000010944 ethyl methyl cellulose Nutrition 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000009975 flexible effect Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 229940014041 hyaluronate Drugs 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 239000002198 insoluble material Substances 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 229920003087 methylethyl cellulose Polymers 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000006082 mold release agent Substances 0.000 description 2
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 102200006535 rs104894361 Human genes 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000010802 sludge Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229940010747 sodium hyaluronate Drugs 0.000 description 2
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000010409 thin film Substances 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 229920003169 water-soluble polymer Polymers 0.000 description 2
- HXFCUMCLVYNZDM-UHFFFAOYSA-N 2-aminoacetic acid;sodium Chemical compound [Na].NCC(O)=O HXFCUMCLVYNZDM-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 244000247812 Amorphophallus rivieri Species 0.000 description 1
- 235000001206 Amorphophallus rivieri Nutrition 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241001260012 Bursa Species 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 229920003043 Cellulose fiber Polymers 0.000 description 1
- 241000561734 Celosia cristata Species 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 244000007835 Cyamopsis tetragonoloba Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical class COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 229920002752 Konjac Polymers 0.000 description 1
- 229920003105 Methocel™ A15 LV Polymers 0.000 description 1
- VGGLHLAESQEWCR-UHFFFAOYSA-N N-(hydroxymethyl)urea Chemical compound NC(=O)NCO VGGLHLAESQEWCR-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- 206010034238 Pelvic adhesions Diseases 0.000 description 1
- 206010034650 Peritoneal adhesions Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000012084 abdominal surgery Methods 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000007675 cardiac surgery Methods 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 description 1
- 229940106681 chloroacetic acid Drugs 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 210000001520 comb Anatomy 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical compound C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920006158 high molecular weight polymer Polymers 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 208000003243 intestinal obstruction Diseases 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000000252 konjac Substances 0.000 description 1
- 235000010485 konjac Nutrition 0.000 description 1
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229940050176 methyl chloride Drugs 0.000 description 1
- 238000007431 microscopic evaluation Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 239000001254 oxidized starch Substances 0.000 description 1
- 235000013808 oxidized starch Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- QUBQYFYWUJJAAK-UHFFFAOYSA-N oxymethurea Chemical compound OCNC(=O)NCO QUBQYFYWUJJAAK-UHFFFAOYSA-N 0.000 description 1
- 229950005308 oxymethurea Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 125000003198 secondary alcohol group Chemical group 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 230000005477 standard model Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000002759 woven fabric Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/042—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/28—Polysaccharides or their derivatives
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Surgery (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2075896P | 1996-06-28 | 1996-06-28 | |
| US20758P | 1996-06-28 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69738462D1 DE69738462D1 (de) | 2008-03-06 |
| DE69738462T2 true DE69738462T2 (de) | 2009-01-15 |
Family
ID=21800405
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69738462T Expired - Lifetime DE69738462T2 (de) | 1996-06-28 | 1997-06-27 | Bioresorbierbare medizinische Vorrichtungen aus oxidierten Polysacchariden |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP0815879B1 (enExample) |
| JP (1) | JPH1066723A (enExample) |
| CN (1) | CN1181980A (enExample) |
| AU (1) | AU725479B2 (enExample) |
| BR (1) | BR9703773A (enExample) |
| CA (1) | CA2208939C (enExample) |
| DE (1) | DE69738462T2 (enExample) |
| ES (1) | ES2299182T3 (enExample) |
| IN (1) | IN192791B (enExample) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2320502B (en) * | 1996-12-20 | 2000-09-20 | Johnson & Johnson Medical | Bioresorbable alginate derivatives |
| US6440940B1 (en) | 1997-12-18 | 2002-08-27 | Peter J. Doyle | Bioresorbable alginate derivatives |
| GB9810127D0 (en) | 1998-05-13 | 1998-07-08 | Ml Lab Plc | Prevention of surgical adhesions |
| CN1181894C (zh) * | 1998-05-13 | 2004-12-29 | ML实验室plc. | 用于预防手术粘连的含糊精的组合物 |
| CN100488490C (zh) * | 2000-04-28 | 2009-05-20 | 生物生命股份有限公司 | 应用血液凝固剂的止血剂、方法和载体 |
| IL153000A0 (en) * | 2000-06-09 | 2003-06-24 | Genzyme Corp | Low molecular weight carboxymethylcellulose compositions and medical implants, devices and pharmaceutical preparations comprising the same |
| WO2002087643A1 (en) * | 2001-04-30 | 2002-11-07 | Beijing Textile Research Institute | Water soluble cellulose etherified derivates styptic materials |
| JP4846147B2 (ja) * | 2001-12-17 | 2011-12-28 | 凸版印刷株式会社 | 酸化多糖類材料を被覆又は含浸させた材料の製造方法 |
| US7252837B2 (en) | 2002-06-28 | 2007-08-07 | Ethicon, Inc. | Hemostatic wound dressing and method of making same |
| US7279177B2 (en) * | 2002-06-28 | 2007-10-09 | Ethicon, Inc. | Hemostatic wound dressings and methods of making same |
| US7700500B2 (en) | 2002-12-23 | 2010-04-20 | Kimberly-Clark Worldwide, Inc. | Durable hydrophilic treatment for a biodegradable polymeric substrate |
| CN1330389C (zh) * | 2003-03-05 | 2007-08-08 | 朱晓明 | 止血凝胶 |
| WO2004080500A1 (en) * | 2003-03-10 | 2004-09-23 | Johnson & Johnson Medical Limited | Hydrocolloid materials for use in wound healing |
| US7019191B2 (en) | 2003-03-25 | 2006-03-28 | Ethicon, Inc. | Hemostatic wound dressings and methods of making same |
| DE10318802A1 (de) * | 2003-04-17 | 2004-11-04 | Aesculap Ag & Co. Kg | Selbsthaftendes resorbierbares Hämostyptikum |
| US20040241212A1 (en) * | 2003-05-30 | 2004-12-02 | Pendharkar Sanyog Manohar | Biodegradable hemostatic wound dressings |
| US20040265371A1 (en) * | 2003-06-25 | 2004-12-30 | Looney Dwayne Lee | Hemostatic devices and methods of making same |
| US7455248B2 (en) * | 2004-03-17 | 2008-11-25 | Genzyme Corporation | Powder delivery device |
| AU2005277397B2 (en) | 2004-08-18 | 2011-08-25 | VERO Biotech LLC. | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
| US7618594B2 (en) | 2004-08-18 | 2009-11-17 | Geno Llc | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
| BRPI0516764B8 (pt) | 2004-10-20 | 2021-05-25 | Ethicon Inc | hemostato |
| US9358318B2 (en) | 2004-10-20 | 2016-06-07 | Ethicon, Inc. | Method of making a reinforced absorbable multilayered hemostatic wound dressing |
| BRPI0516220B8 (pt) * | 2004-10-20 | 2021-06-22 | Ethicon Inc | tecido de multicamadas absorvíveis reforçadas para aplicação em dispositivos médicos e método de fabricação |
| FR2898502B1 (fr) * | 2006-03-16 | 2012-06-15 | Sofradim Production | Tissu prothetique tridimensionnel a face dense resorbable |
| US8252333B2 (en) | 2006-01-26 | 2012-08-28 | Jorge Cueto-Garcia | Biodegradable, non-toxic biological adhesive for use in abdominal surgery |
| DE102006020498A1 (de) * | 2006-04-20 | 2007-10-25 | Aesculap Ag & Co. Kg | Schichtförmige Wundauflage |
| US8313762B2 (en) * | 2006-07-05 | 2012-11-20 | Medtronic Xomed, Inc. | Flexible bioresorbable hemostatic packing and stent |
| CN101313915B (zh) * | 2007-05-30 | 2011-04-20 | 北京泰克美科技有限公司 | 透明质酸及其盐、交联透明质酸及其盐在制备治疗或预防海泡伤药物中的应用 |
| CN101121041A (zh) * | 2007-08-09 | 2008-02-13 | 美国淀粉医疗公司 | 变性淀粉可吸收性止血材料及其制备方法 |
| CA2713049C (en) | 2008-01-28 | 2017-02-28 | Geno Llc | Conversion of nitrogen dioxide (no2) to nitric oxide (no) |
| US9376648B2 (en) | 2008-04-07 | 2016-06-28 | The Procter & Gamble Company | Foam manipulation compositions containing fine particles |
| JP5757861B2 (ja) | 2008-04-24 | 2015-08-05 | メドトロニック，インコーポレイテッド | キトサン−含有保護用組成物 |
| CN102065849B (zh) | 2008-04-24 | 2015-04-29 | 麦德托尼克公司 | 基于壳聚糖和氧化多糖的保护性凝胶 |
| EP2291448B1 (en) * | 2008-04-24 | 2017-01-04 | Medtronic, Inc | Rehydratable polysaccharide particles and sponge |
| EP2291524A2 (en) | 2008-04-24 | 2011-03-09 | Medtronic, Inc | Rehydratable thiolated polysaccharide particles and sponge |
| US8607785B2 (en) | 2008-08-21 | 2013-12-17 | Geno Llc | Systems and devices for generating nitric oxide |
| US8173072B2 (en) * | 2008-09-22 | 2012-05-08 | Geno Llc | Conversation of nitrogen dioxide (NO2) to nitric oxide (NO) |
| JP5024262B2 (ja) * | 2008-10-16 | 2012-09-12 | 凸版印刷株式会社 | 酸化多糖類材料を被覆又は含浸させた材料および生体適合材料 |
| EP2445508B1 (en) | 2009-06-22 | 2018-11-14 | VERO Biotech LLC | Nitric oxide therapies |
| US8349354B2 (en) * | 2009-09-22 | 2013-01-08 | Ethicon, Inc. | Composite layered hemostasis device |
| DE102009053305A1 (de) | 2009-11-12 | 2011-08-18 | medichema GmbH, 09112 | Verfahren zur Herstellung einer schichtförmigen Wundauflage |
| KR101070358B1 (ko) | 2009-12-24 | 2011-10-05 | 한국생산기술연구원 | 의료용 부직포 및 그의 제조방법 |
| US8409526B2 (en) * | 2010-12-09 | 2013-04-02 | General Electric Company | Cellulose substrates, compositions and methods for storage and analysis of biological materials |
| US9987115B2 (en) * | 2011-03-30 | 2018-06-05 | Boston Scientific Scimed, Inc. | Film encapsulated pelvic implant system and method |
| CN102350006A (zh) * | 2011-10-25 | 2012-02-15 | 中国纺织科学研究院 | 医用湿性复合敷料及其制造方法 |
| CN102912622B (zh) * | 2012-10-30 | 2014-07-09 | 威高集团有限公司 | 一种具有表层纳米结构的氧化再生纤维素类止血材料的制备方法 |
| EP2935688A2 (en) * | 2012-12-20 | 2015-10-28 | ConvaTec Technologies Inc. | Processing of chemically modified cellulosic fibres |
| CN103480033B (zh) * | 2013-10-08 | 2015-10-28 | 江苏昌吉永生物科技有限公司 | 一种医用生物多糖止血愈合海绵及其制备方法 |
| CN103603182B (zh) * | 2013-11-05 | 2016-01-13 | 王学洲 | 可溶性止血纱布及其制备方法 |
| US10227478B2 (en) | 2014-07-24 | 2019-03-12 | Smith & Nephew, Inc. | Resilient foams and uses thereof |
| CN104689365A (zh) * | 2015-03-11 | 2015-06-10 | 中南大学 | 一种促创面愈合的复合生物敷料及其制备方法 |
| CN111840633B (zh) * | 2019-04-29 | 2022-08-23 | 上海硅健生物材料有限公司 | 一种皮肤修复膜及其制备方法 |
| CN112107721A (zh) * | 2020-10-22 | 2020-12-22 | 伊索曼(中山)医疗器械有限公司 | 具有生物效应的合成敷料及其制备方法 |
| US20240099804A1 (en) * | 2021-02-16 | 2024-03-28 | Cornell University | Polysaccharide-glycerol penetration-resistant compositions and surgical barriers made therefrom |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB779820A (en) * | 1954-04-05 | 1957-07-24 | Harry Pauling | Process for the production of cellulose or cellulose containing material having acid properties |
| US4543410A (en) * | 1982-06-21 | 1985-09-24 | Morca, Inc. | Absorbent cellulosic base structures |
| JP2637782B2 (ja) * | 1987-08-12 | 1997-08-06 | エチコン・インコーポレーテツド | 再吸収可能な外科用網およびそれから製造された人工器官 |
| US5180398A (en) * | 1990-12-20 | 1993-01-19 | Johnson & Johnson Medical, Inc. | Cellulose oxidation by a perfluorinated hydrocarbon solution of nitrogen dioxide |
-
1997
- 1997-06-25 IN IN1209CA1997 patent/IN192791B/en unknown
- 1997-06-26 CA CA002208939A patent/CA2208939C/en not_active Expired - Lifetime
- 1997-06-26 AU AU27540/97A patent/AU725479B2/en not_active Expired
- 1997-06-27 JP JP9208254A patent/JPH1066723A/ja active Pending
- 1997-06-27 EP EP97304606A patent/EP0815879B1/en not_active Expired - Lifetime
- 1997-06-27 ES ES97304606T patent/ES2299182T3/es not_active Expired - Lifetime
- 1997-06-27 DE DE69738462T patent/DE69738462T2/de not_active Expired - Lifetime
- 1997-06-28 CN CN97117113.0A patent/CN1181980A/zh active Pending
- 1997-06-30 BR BR9703773A patent/BR9703773A/pt not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| DE69738462D1 (de) | 2008-03-06 |
| AU2754097A (en) | 1998-01-22 |
| CA2208939C (en) | 2007-09-18 |
| EP0815879B1 (en) | 2008-01-16 |
| IN192791B (enExample) | 2004-05-22 |
| JPH1066723A (ja) | 1998-03-10 |
| CN1181980A (zh) | 1998-05-20 |
| BR9703773A (pt) | 1998-11-10 |
| EP0815879A3 (en) | 1999-12-22 |
| MX9704971A (es) | 1998-05-31 |
| CA2208939A1 (en) | 1997-12-28 |
| ES2299182T3 (es) | 2008-05-16 |
| EP0815879A2 (en) | 1998-01-07 |
| AU725479B2 (en) | 2000-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69738462T2 (de) | Bioresorbierbare medizinische Vorrichtungen aus oxidierten Polysacchariden | |
| DE69838614T2 (de) | Zusammensetzungen von Carboxypolysaccharid-Polyetherkomplexen zur Verwendung zum Vermindern chirurgischer Verwachsungen | |
| US20030073663A1 (en) | Bioabsorbable medical devices from oxidized polysaccharides | |
| DE60108258T2 (de) | Selbstklebende, hydratierbare matrix für therapeutische anwendungen | |
| DE69805166T2 (de) | Collagenmaterial geeignet für die hemmung der postoperativen adhäsion | |
| DE69634823T2 (de) | Aus hyaluronsäurederivaten bestehenden biomaterialien zur hemmung der postoperativen adhäsionsbildung | |
| US6869938B1 (en) | Compositions of polyacids and polyethers and methods for their use in reducing adhesions | |
| DE69721388T2 (de) | Oxidierte Zellulose enthaltendes Verbundmaterial zur Verminderung von postoperativen Adhäsionen | |
| DE69817574T2 (de) | Herstellungsmethode für ein faserfreies, poröses material | |
| US9675728B2 (en) | Compositions for wound treatment | |
| DE69125609T2 (de) | Wasserunlösliche Hyaluronsäureabkömmlinge | |
| US20050074495A1 (en) | Compositions of polyacids and methods for their use in reducing adhesions | |
| CA2366880C (en) | Compositions of polyacids and polyethers and methods for their use in reducing adhesions | |
| Falabella et al. | Novel macromolecular crosslinking hydrogel to reduce intra-abdominal adhesions | |
| DE602004002908T2 (de) | Postchirurgische Antiadhäsionsschicht bestehend aus Carboxymethylchitosan und Carboxymethylcellulose und ihr Herstellungsverfahren | |
| Sivakumar et al. | Ferulic acid loaded microspheres reinforced in 3D hybrid scaffold for antimicrobial wound dressing | |
| CA2578678C (en) | Photoreactive polysaccharide, photocrosslinked polysaccharide products, the method of making them and medical materials therefrom | |
| DE69508356T2 (de) | Wundverband | |
| WO2002030480A1 (de) | Biokompatibles verbundmaterial für medizinische anwendungen | |
| KR20020012170A (ko) | 폴리산과 폴리에테르의 조성물 및 이들을 유착 방지에이용하는 방법 | |
| Dik et al. | Polymer-based anti-adhesive barriers: A comprehensive overview of current approaches for medical and biological applications | |
| MXPA97004971A (en) | Biabsorbible medical devices from polyacaridos oxida | |
| JPWO2001034214A1 (ja) | 水難溶性化した可溶性セルロース誘導体の用途及びその製造方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |